Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04279405 | A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies | PHASE1 | COMPLETED | 43 | — | — | Jun 15, 2020 | Jun 1, 2023 | Jun 13, 2024 | 1 | China |
incidence of adverse events and associated dose of YY-20394
the percentage of participants achieving a complete response or partial response
the percentage of participants achieving a complete response or partial response or stable disease
| Arm | Type | Description |
|---|---|---|
| YY-20394 | EXPERIMENTAL | treatment with YY-20394 will be continued until tumor progression or development of unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| YY-20394 | DRUG | YY-20394 80mg tablet administered orally once daily |
Inclusion Criteria: * histologically or cytologically confirmed relapse and/or refractory B cell hematologic malignancies(Excluding follicular lymphoma) * prior treatment with ≥1 prior standard anti-tumor regimens and 2 courses of treatments at least * eastern cooperative oncology group performance...